Hikma Pharmaceuticals (LON:HIK) Stock Rating Reaffirmed by Jefferies Financial Group

Hikma Pharmaceuticals (LON:HIK – Get Rating)‘s stock had its “buy” rating reaffirmed by analysts at Jefferies Financial Group in a research note issued to investors on Wednesday, Marketbeat reports. They currently have a GBX 2,080 ($25.76) target price on the stock. Jefferies Financial Group’s price target suggests a potential upside of 16.85% from the company’s […]

Related Keywords

Canada ,Deneen Vojta ,Royal Bank ,Citigroup ,Berenberg Bank ,Hikma Pharmaceuticals Trading ,Hikma Pharmaceuticals ,Barclays ,Jefferies Financial Group ,News Ratings For Hikma Pharmaceuticals Daily ,Analyst Recommendations For Hikma Pharmaceuticals ,Jpmorgan Chase Co ,Get Rating ,Financial Group ,Hikma Pharmaceuticals Daily ,Lon Hik ,Zhik ,Medical ,Reiterated Rating ,Jefferies Financial Group Inc ,